Cardiac contractility modulation therapy in elderly patients with chronic heart failure: results of the 12-month follow-up
https://doi.org/10.35336/VA-2021-2-5-10
Abstract
Aim. This study aimed to evaluate the efficacy and safety of cardiac contractility modulation (CCM) therapy in elderly patients with heart failure with reduced ejection fraction (HFrEF).
Methods. Sixteen patients older than 65 years old (median age 70 years) undergoing CCM Optimizer (Impulse Dynamics) device implantation due to HFrEF (NYHA class II - 9 (56%), III - 4 (25%), IV - 3 (19%)) were enrolled in this two-center observational study. Before implantation 6-minute walk test (6MWT), transthoracic echocardiography (TTE) was performed on all patients, and NTproBNP levels were assessed. The follow-up duration was 12 months with 2, 6, 12-month follow-up visits. Control 6MWT, TTE and NTproBNP tests were performed at 6-month and 12-month follow-up visits.
Results. Two patients died during follow-up due to HF decompensation. The remaining patients showed a significant improvement in 6MWT (350 m vs 402.5 m, p=0,01). We also noted a tendency towards the left ventricular EF improvement (33% vs 40%, p=0,2) and lower values of NTproBNP levels (1112 pg/ml vs 527 pg/ml, p=0,19).
Conclusion. CCM therapy is a safe and efficient additional treatment option to manage elderly patients with HFrEF for reducing signs and symptoms of HF.
About the Authors
I. A. Chugunov
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Chugunov Ivan
Moscow, Petroverigsky lane 10 c. 3
K. V. Davtyan
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow, Petroverigsky lane 10 c. 3
A. H. Topchyan
National Medical Research Center for Therapy and Preventive Medicine
Russian Federation
Russian Federation
Moscow, Petroverigsky lane 10 c. 3
N. A. Mironova
National Medical Research Center of Cardiology
Russian Federation
Russian Federation
Moscow, 3rd Cherepkovskaya 13A
E. M. Gupalo
National Medical Research Center of Cardiology
Russian Federation
Russian Federation
Moscow, 3rd Cherepkovskaya 13A
References
1. Imai M, Rastogi S, Gupta RC, et al. Therapy With Cardiac Contractility Modulation Electrical Signals Improves Left Ventricular Function and Remodeling in Dogs With Chronic Heart Failure. J Am Coll Cardiol. 2007;49(21): 2120-8. https://doi.org/10.1016/j.jacc.2006.10.082.
2. Butter C, Rastogi S, Minden HH, et al. Cardiac Contractility Modulation Electrical Signals Improve Myocardial Gene Expression in Patients With Heart Failure. J Am Coll Cardiol. 2008;51(18): 1784-9. https://doi.org/10.1016/j.jacc.2008.01.036.
3. Kleemann T. Kardiale Kontraktilitätsmodulation: Eine neue Therapieform für herzinsuffiziente Patienten mit schmalem Kammerkomplex? Herz. 2015;40(7): 945-51. https://doi.org/10.1007/s00059-015-4362-8.
4. Borggrefe MM, Lawo T, Butter C, et al. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J. 2008;29: 1019-28. https://doi.org/10.1016/j.jacc.2008.01.036.
5. Kadish A, Nademanee K, Volosin K, et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J. 2011;161(2): 329-337.e2. https://doi.org/10.1016/j.ahj.2010.10.025.
6. Abraham WT, Kuck KH, Goldsmith RL, et al. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. JACC Hear Fail. 2018;6(10): 874-83. https://doi.org/10.1016/j.ahj.2010.10.025.
7. Nägele H, Behrens S, Eisermann C. Cardiac contractility modulation in non-responders to cardiac resynchronization therapy. JACC: Heart Failure. 2008;10(12): 1375-80. https://doi.org/10.1016/j.jchf.2018.04.010.
8. Anker SD, Borggrefe M, Neuser H, et al. Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction. Eur J Heart Fail. 2019;21(9): 1103-13. https://doi.org/10.1002/ejhf.1374.
9. Gustafsson F, Torppedersen C, Seibak M, et al. Effect of age on short and long-term mortality in patients admitted to hospital with congestive heart failure. Eur Heart J. 2004;25(19): 1711-7. https://doi.org/10.1016/j.ehj.2004.07.007.
10. Lund LH, Jurga J, Edner M, et al. Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. Eur Heart J. 2013;34(7): 529-39. https://doi.org/10.1093/eurheartj/ehs305.
11. Kuschyk J, Nägele H, Heinz-Kuck K, et al. Cardiac contractility modulation treatment in patients with symptomatic heart failure despite optimal medical therapy and cardiac resynchronization therapy (CRT). Int J Cardiol. 2019;277: 173-7. https://doi.org/10.1016/j.ijcard.2018.10.086.
12. Al-Ghamdi B, Shafquat A, Mallawi Y. Cardiac contractility modulation therapy: Are there superresponders? Hear Case Reports. 2017;3(4): 229-32. https://doi.org/10.1016/j.hrcr.2017.02.004.
13. Swindle JP, Rich MW, McCann P, et al. Implantable cardiac device procedures in older patients: Use and in-hospital outcomes. Arch Intern Med. 2010;170(7): 631- 7. https://doi.org/10.1001/archinternmed.2010.30.
Review
For citations:
Chugunov I.A., Davtyan K.V., Topchyan A.H., Mironova N.A., Gupalo E.M. Cardiac contractility modulation therapy in elderly patients with chronic heart failure: results of the 12-month follow-up. Journal of Arrhythmology. 2021;28(2):5-10. (In Russ.) https://doi.org/10.35336/VA-2021-2-5-10
Views:
438
Email this article 